HRP20240041T1 - Vrlo snažna kisela alfa-glukozidaza s pojačanim ugljikohidratima - Google Patents
Vrlo snažna kisela alfa-glukozidaza s pojačanim ugljikohidratima Download PDFInfo
- Publication number
- HRP20240041T1 HRP20240041T1 HRP20240041TT HRP20240041T HRP20240041T1 HR P20240041 T1 HRP20240041 T1 HR P20240041T1 HR P20240041T T HRP20240041T T HR P20240041TT HR P20240041 T HRP20240041 T HR P20240041T HR P20240041 T1 HRP20240041 T1 HR P20240041T1
- Authority
- HR
- Croatia
- Prior art keywords
- rhgaa
- preparation
- glycans
- average
- preparation according
- Prior art date
Links
- 108010028144 alpha-Glucosidases Proteins 0.000 title claims 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 title 1
- 235000014633 carbohydrates Nutrition 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims 16
- 102000045921 human GAA Human genes 0.000 claims 16
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims 5
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims 4
- 230000000144 pharmacologic effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims 2
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 claims 2
- 229960001512 miglustat Drugs 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 102000016679 alpha-Glucosidases Human genes 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 201000004502 glycogen storage disease II Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Pripravak koji sadrži rekombinantnu ljudsku kiselu alfa-glukozidazu (rhGAA) koju proizvode stanice jajnika kineskog hrčka, naznačen time što su 40%-60% ukupnih N-glikana na rhGAA u pripravku kompleksni tip N-glikana; i pri čemu je prosječni sadržaj N-glikana koji nose manoza-6-fosfat (M6P) u rasponu od 3,0 do 5,0 mola po molu rhGAA.
2. Pripravak prema zahtjevu 1, naznačen time što je prosječni sadržaj N-glikana koji nose M6P u rasponu od 3,0 do 4,0 mola po molu rhGAA.
3. Pripravak prema zahtjevu 1, naznačen time što je prosječni sadržaj N-glikana koji nose M6P u rasponu od 4,0 do 5,0 mola po molu rhGAA.
4. Pripravak prema bilo kojem od zahtjeva 1-3, naznačen time što u prosjeku N-glikani sadrže više od 4 mola sijalične kiseline po molu rhGAA.
5. Pripravak prema bilo kojem od zahtjeva 1-3, naznačen time što rhGAA sadrži u prosjeku 2,0 do 8,0 mol ostataka sijalične kiseline po molu rhGAA.
6. Pripravak prema bilo kojem od zahtjeva 1-5, naznačen time što rhGAA sadrži u prosjeku najmanje jedan bis-fosforilirani N-glikan po rhGAA.
7. Pripravak prema bilo kojem od zahtjeva 1-6, naznačen time što su 45%-55% ukupnih N-glikana na rhGAA u pripravku kompleksni tip N-glikana.
8. Pripravak prema bilo kojem od zahtjeva 1-7, naznačen time što su 50% ukupnih N-glikana na rhGAA u pripravku kompleksni tip N-glikana.
9. Pripravak prema bilo kojem od zahtjeva 1-8, naznačen time što prosječni sadržaj N-glikana koji nose M6P iznosi 4 mola po molu rhGAA, te pri čemu rhGAA sadrži u prosjeku 4,5 mola ostataka sijalične kiseline po molu rhGAA i u prosjeku najmanje jedan bis-fosforilirani N-glikan po rhGAA.
10. Pripravak prema bilo kojem od zahtjeva 1-9, naznačen time što nadalje sadrži farmakološki pratilac.
11. Pripravak prema zahtjevu 10, naznačen time što je farmakološki pratilac odabran iz skupine koju čine 1-deoksinojirimicin ili njegova sol i N-butil-deoksinojirimicin ili njegova sol.
12. Pripravak prema bilo kojem od zahtjeva 1-11, za upotrebu u liječenju Pompeove bolesti.
13. Pripravak za upotrebu prema zahtjevu 12, naznačen time što se navedeni pripravak primjenjuje na (a) srčani mišić subjekta, (b) kvadriceps, triceps ili drugi skeletni mišić subjekta, ili (c) dijafragmu subjekta.
14. Pripravak za upotrebu prema zahtjevu 12 ili zahtjevu 13, naznačen time što je navedeni pripravak kombiniran s, primijenjen zajedno s, ili odvojeno primijenjen zajedno s farmakološkim pratiocem.
15. Pripravak za upotrebu prema zahtjevu 14, naznačen time što je farmakološki pratilac odabran iz skupine koju čine 1-deoksinojirimicin ili njegova sol i N-butil-deoksinojirimicin ili njegova sol.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462057842P | 2014-09-30 | 2014-09-30 | |
US201462057847P | 2014-09-30 | 2014-09-30 | |
US201562112463P | 2015-02-05 | 2015-02-05 | |
US201562135345P | 2015-03-19 | 2015-03-19 | |
PCT/US2015/053252 WO2016054231A1 (en) | 2014-09-30 | 2015-09-30 | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
EP15845664.0A EP3201320B1 (en) | 2014-09-30 | 2015-09-30 | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240041T1 true HRP20240041T1 (hr) | 2024-03-29 |
Family
ID=55631441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240041TT HRP20240041T1 (hr) | 2014-09-30 | 2015-09-30 | Vrlo snažna kisela alfa-glukozidaza s pojačanim ugljikohidratima |
Country Status (36)
Country | Link |
---|---|
US (5) | US10208299B2 (hr) |
EP (2) | EP4273241A3 (hr) |
JP (3) | JP6851964B2 (hr) |
KR (3) | KR20220146662A (hr) |
CN (2) | CN107075468B (hr) |
AU (2) | AU2015325028B2 (hr) |
BR (1) | BR112017005810A2 (hr) |
CA (2) | CA3228032A1 (hr) |
CL (1) | CL2017000722A1 (hr) |
CO (1) | CO2017002776A2 (hr) |
CR (1) | CR20170107A (hr) |
DK (1) | DK3201320T3 (hr) |
DO (1) | DOP2017000079A (hr) |
EA (1) | EA038986B1 (hr) |
EC (1) | ECSP17019103A (hr) |
ES (1) | ES2967620T3 (hr) |
FI (2) | FI3201320T3 (hr) |
FR (1) | FR24C1012I1 (hr) |
HR (1) | HRP20240041T1 (hr) |
HU (2) | HUE064629T2 (hr) |
IL (4) | IL307587A (hr) |
LT (1) | LT3201320T (hr) |
MX (2) | MX2017003989A (hr) |
MY (1) | MY186336A (hr) |
NI (1) | NI201700039A (hr) |
PE (1) | PE20170906A1 (hr) |
PH (1) | PH12017500455A1 (hr) |
PL (1) | PL3201320T3 (hr) |
PT (1) | PT3201320T (hr) |
RS (1) | RS65066B1 (hr) |
SG (2) | SG11201702114TA (hr) |
SI (1) | SI3201320T1 (hr) |
SV (1) | SV2017005416A (hr) |
TN (1) | TN2017000082A1 (hr) |
WO (1) | WO2016054231A1 (hr) |
ZA (2) | ZA201701945B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10208299B2 (en) | 2014-09-30 | 2019-02-19 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
BR112018013151A2 (pt) * | 2015-12-30 | 2018-12-18 | Amicus Therapeutics Inc | alfa-glicosidase ácida aumentada para o tratamento da doença de pompe |
PT3957320T (pt) * | 2015-12-30 | 2023-11-23 | Amicus Therapeutics Inc | Alfa-glicosidase ácida aumentada para o tratamento da doença de pompe |
TWI759291B (zh) * | 2016-03-30 | 2022-04-01 | 美商阿米庫斯醫療股份有限公司 | 用於選擇高m6p重組蛋白之方法 |
KR102455821B1 (ko) * | 2016-03-30 | 2022-10-18 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 고 m6p 재조합 단백질의 선택 방법 |
KR20240001291A (ko) | 2016-03-30 | 2024-01-03 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
MX2019013624A (es) * | 2017-05-15 | 2020-01-13 | Amicus Therapeutics Inc | Alfa-glucosidasa acida humana recombinante. |
JP2022546587A (ja) | 2019-09-06 | 2022-11-04 | アミカス セラピューティックス インコーポレイテッド | 生物製剤の捕捉及び精製のための方法 |
TW202245830A (zh) * | 2021-02-11 | 2022-12-01 | 美商阿米庫斯醫療股份有限公司 | 重組人類酸性α-葡萄糖苷酶及其用途 |
WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
TW202400212A (zh) * | 2022-05-05 | 2024-01-01 | 美商阿米庫斯醫療股份有限公司 | 用於治療龐貝氏病之方法 |
WO2024119091A1 (en) * | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Fexamethods for treating infantile-onset pompe disease in pediatric patients |
WO2024119070A1 (en) * | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Methods for treating late onset pompe disease in pediatric patients |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
ATE258919T1 (de) | 1997-11-10 | 2004-02-15 | Searle & Co | Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz |
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
KR20010101131A (ko) | 1998-12-07 | 2001-11-14 | 추후기재 | 폼페병의 치료 방법 |
US6545021B1 (en) | 1999-02-12 | 2003-04-08 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
CA2378776A1 (en) | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
EP2767291B1 (en) | 2000-07-18 | 2016-09-14 | Duke University | Treatment of glycogen storage disease type II |
CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
CN1604788B (zh) | 2001-10-16 | 2013-04-17 | 里克斯金蒂克斯公司 | 高浓度蛋白制剂及其制备方法 |
WO2003086452A2 (en) | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
PT2441467E (pt) | 2003-01-31 | 2015-10-12 | Sinai School Medicine | Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica |
FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
BRPI0507440A (pt) * | 2004-02-06 | 2007-07-10 | Biomarin Pharm Inc | fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas |
AU2005212435B2 (en) | 2004-02-10 | 2010-09-09 | Biomarin Pharmaceutical Inc. | Acid alpha-glucosidase and fragments thereof |
US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
EP3441090A1 (en) | 2005-05-17 | 2019-02-13 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
WO2008063511A2 (en) | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
CN101636200A (zh) * | 2006-11-13 | 2010-01-27 | 齐斯特治疗公司 | 用于治疗庞贝氏症的方法 |
WO2008112525A2 (en) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Treatment of lysosomal storage diseases |
MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
WO2009066069A1 (en) | 2007-11-21 | 2009-05-28 | Summit Corporation Plc | Treatment of protein folding disorders |
WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
HUE051377T2 (hu) | 2008-02-12 | 2021-03-01 | Amicus Therapeutics Inc | Eljárás betegségek gyógyászati chaperonnal történõ kezelésére adott válasz elõrejelzésére |
JP2011512876A (ja) | 2008-03-12 | 2011-04-28 | アミカス セラピューティックス インコーポレイテッド | 特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視 |
CA2718059A1 (en) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for pompe disease |
WO2009137721A2 (en) * | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
WO2010056746A1 (en) | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
CN103432566A (zh) * | 2008-12-16 | 2013-12-11 | 建新公司 | 寡糖-蛋白缀合物 |
US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
JP5645918B2 (ja) | 2009-04-09 | 2014-12-24 | アミカス セラピューティックス インコーポレイテッド | リソソーム蓄積障害の予防および/または治療方法 |
EP3075386B1 (en) | 2009-06-17 | 2019-10-16 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
JP5415170B2 (ja) | 2009-07-21 | 2014-02-12 | 富士フイルム株式会社 | 複眼撮像装置 |
WO2011039634A2 (en) * | 2009-09-29 | 2011-04-07 | Universiteit Gent | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
WO2011109600A1 (en) | 2010-03-05 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
SG189108A1 (en) * | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
CN103797115A (zh) | 2011-04-22 | 2014-05-14 | 建新公司 | 具有快速加工性能的经过修饰的酸性α葡糖苷酶 |
US9545450B2 (en) * | 2011-05-27 | 2017-01-17 | Amicus Therapeutics Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
EP2735064A2 (en) * | 2011-07-22 | 2014-05-28 | Insight Photonic Solutions, Inc. | System and method of dynamic and adaptive creation of a wavelength-continuous and prescribed wavelength versus time sweep from a laser |
JP6320931B2 (ja) | 2011-12-22 | 2018-05-09 | セントジーン アイピー ゲーエムベーハー | リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび/またはアンブロキソールの誘導体の組み合わせ |
KR20200032244A (ko) | 2012-03-07 | 2020-03-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
US20150086530A1 (en) * | 2012-05-03 | 2015-03-26 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of pompe disease |
WO2013182652A1 (en) | 2012-06-06 | 2013-12-12 | Fondazione Telethon | Allosteric chaperones and uses thereof |
TWI529396B (zh) | 2014-07-18 | 2016-04-11 | Mpi Corp | Probe card and its transfer circuit board and signal feed structure |
US10208299B2 (en) | 2014-09-30 | 2019-02-19 | Amicus Therapeutics, Inc. | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
-
2015
- 2015-09-30 US US15/515,808 patent/US10208299B2/en active Active
- 2015-09-30 CR CR20170107A patent/CR20170107A/es unknown
- 2015-09-30 SG SG11201702114TA patent/SG11201702114TA/en unknown
- 2015-09-30 IL IL307587A patent/IL307587A/en unknown
- 2015-09-30 BR BR112017005810A patent/BR112017005810A2/pt not_active Application Discontinuation
- 2015-09-30 PL PL15845664.0T patent/PL3201320T3/pl unknown
- 2015-09-30 CA CA3228032A patent/CA3228032A1/en active Pending
- 2015-09-30 LT LTEPPCT/US2015/053252T patent/LT3201320T/lt unknown
- 2015-09-30 CN CN201580052512.5A patent/CN107075468B/zh active Active
- 2015-09-30 HU HUE15845664A patent/HUE064629T2/hu unknown
- 2015-09-30 DK DK15845664.0T patent/DK3201320T3/da active
- 2015-09-30 EP EP23191307.0A patent/EP4273241A3/en active Pending
- 2015-09-30 HR HRP20240041TT patent/HRP20240041T1/hr unknown
- 2015-09-30 KR KR1020227035610A patent/KR20220146662A/ko not_active Application Discontinuation
- 2015-09-30 SG SG10202003753PA patent/SG10202003753PA/en unknown
- 2015-09-30 IL IL289383A patent/IL289383B2/en unknown
- 2015-09-30 KR KR1020217030450A patent/KR102455814B1/ko active IP Right Grant
- 2015-09-30 EP EP15845664.0A patent/EP3201320B1/en active Active
- 2015-09-30 MX MX2017003989A patent/MX2017003989A/es unknown
- 2015-09-30 JP JP2017516917A patent/JP6851964B2/ja active Active
- 2015-09-30 TN TN2017000082A patent/TN2017000082A1/en unknown
- 2015-09-30 ES ES15845664T patent/ES2967620T3/es active Active
- 2015-09-30 SI SI201531983T patent/SI3201320T1/sl unknown
- 2015-09-30 EA EA201790724A patent/EA038986B1/ru unknown
- 2015-09-30 WO PCT/US2015/053252 patent/WO2016054231A1/en active Application Filing
- 2015-09-30 RS RS20240027A patent/RS65066B1/sr unknown
- 2015-09-30 MY MYPI2017000365A patent/MY186336A/en unknown
- 2015-09-30 PT PT158456640T patent/PT3201320T/pt unknown
- 2015-09-30 KR KR1020177011346A patent/KR102306577B1/ko active Application Filing
- 2015-09-30 CA CA2961762A patent/CA2961762C/en active Active
- 2015-09-30 FI FIEP15845664.0T patent/FI3201320T3/fi active
- 2015-09-30 PE PE2017000507A patent/PE20170906A1/es unknown
- 2015-09-30 AU AU2015325028A patent/AU2015325028B2/en active Active
- 2015-09-30 CN CN202111483006.5A patent/CN114540327A/zh active Pending
-
2017
- 2017-03-10 PH PH12017500455A patent/PH12017500455A1/en unknown
- 2017-03-14 IL IL251152A patent/IL251152B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01945A patent/ZA201701945B/en unknown
- 2017-03-20 DO DO2017000079A patent/DOP2017000079A/es unknown
- 2017-03-23 CO CONC2017/0002776A patent/CO2017002776A2/es unknown
- 2017-03-27 MX MX2021014565A patent/MX2021014565A/es unknown
- 2017-03-27 CL CL2017000722A patent/CL2017000722A1/es unknown
- 2017-03-28 NI NI201700039A patent/NI201700039A/es unknown
- 2017-03-28 EC ECIEPI201719103A patent/ECSP17019103A/es unknown
- 2017-03-28 SV SV2017005416A patent/SV2017005416A/es unknown
-
2019
- 2019-01-18 US US16/252,505 patent/US10961522B2/en active Active
- 2019-03-19 ZA ZA2019/01690A patent/ZA201901690B/en unknown
-
2020
- 2020-09-23 IL IL277529A patent/IL277529B/en unknown
- 2020-09-25 JP JP2020161470A patent/JP7225176B2/ja active Active
-
2021
- 2021-02-23 US US17/249,175 patent/US11753632B2/en active Active
-
2022
- 2022-02-04 US US17/665,179 patent/US11591583B2/en active Active
- 2022-05-24 AU AU2022203498A patent/AU2022203498A1/en active Pending
-
2023
- 2023-02-08 JP JP2023017964A patent/JP2023078118A/ja active Pending
- 2023-02-17 US US18/111,321 patent/US20230203465A1/en active Pending
-
2024
- 2024-03-28 FR FR24C1012C patent/FR24C1012I1/fr active Active
- 2024-04-02 HU HUS2400007C patent/HUS2400007I1/hu unknown
- 2024-04-03 FI FIC20240010C patent/FIC20240010I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240041T1 (hr) | Vrlo snažna kisela alfa-glukozidaza s pojačanim ugljikohidratima | |
MY194870A (en) | Stuffy nose deblocking composition having antiviral activity | |
CN102836089B (zh) | 喷雾护肤化妆品组合物及其应用 | |
NZ716977A (en) | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases | |
BR112015011244A2 (pt) | Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica | |
BR112015005048A2 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
RS54905B1 (sr) | Poboljšani rekombinantni humani folikulo-stimulišući hormon | |
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
HRP20211497T1 (hr) | Proizvodnja rekombinantnog lubricina | |
EP3228311A3 (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
BR112012026596A2 (pt) | método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas | |
PH12015501623A1 (en) | Glyco-modified atrial natriuretic peptide | |
RS53783B1 (en) | INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM | |
EA201590937A1 (ru) | Замещенные анионные соединения, имеющие скелет, образованный из небольшого числа сахаридных звеньев | |
BR112016012838A2 (pt) | Composição para a administração oral de um agente bioativo incluindo partículas que compreendem um agente bioativo e um polímero mucoadesivo em uma solução aquosa, e, método de preparação da composição | |
BR112015011764A2 (pt) | composições de baixo teor de sal de sódio e métodos de produção e utilização | |
BR112014030680A2 (pt) | forma de dosagem efervescente | |
PH12016500025A1 (en) | Methods for promoting neuronal development and/or health | |
BR112015018421A2 (pt) | composição nutricional anti-regurgitação | |
MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
BR112016028973A2 (pt) | composições antagonistas de receptor de sabor doce | |
WO2015061464A3 (en) | Recombinant glycoproteins and uses thereof | |
WO2014142469A3 (ko) | 안과 염증 질환 치료용 점안제 조성물 및 이의 제조 방법 | |
BR112015010675A8 (pt) | composição de higiene oral compreendendo copolímero de blocos e método para proteger esmalte dos dentes de erosão ácida” |